Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
RP1 is an engineered oncolytic type-I herpes simplex virus (HSV-1) strain, which potentially induces an anti-tumor immune response and tumor cell lysis (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|RP1||HSV-1 RP1||RP1 is an engineered oncolytic type-I herpes simplex virus (HSV-1) strain, which potentially induces an anti-tumor immune response and tumor cell lysis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03767348||Phase Ib/II||Nivolumab + RP1 RP1||Study of RP1 Monotherapy and RP1 in Combination With Nivolumab||Recruiting||USA | FRA | ESP | DEU||1|
|NCT04050436||Phase II||Cemiplimab + RP1 RP1||Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)||Recruiting||USA | ITA | FRA | ESP | DEU | CAN||4|